On November 12, 2026 Olema Oncology, Inc. (formerly Olema Pharmaceuticals, Inc.) ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, reported that, effective today, it has changed its corporate name from "Olema Pharmaceuticals, Inc." to "Olema Oncology, Inc." pursuant to the Company’s Eighth Amended and Restated Certificate of Incorporation filed with the Secretary of State of Delaware.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company’s common stock will continue to be listed and trade on the Nasdaq Global Select Market under the ticker symbol "OLMA." Pursuant to Delaware law, no action was required by stockholders of the Company to effect the name change. Stock certificates reflecting the prior corporate name will continue to be valid.

(Press release, Olema Oncology, NOV 12, 2026, View Source [SID1234674723])